Lori Winn v. HHS - Influenza, Guillain-Barre Syndrome (GBS) (2020)
Case summary [AI summaries can sometimes make mistakes]
Lori Winn filed a petition for compensation under the National Vaccine Injury Compensation Program on October 1, 2020, alleging she suffered Guillain-Barre Syndrome (GBS) after receiving an influenza vaccine on November 2, 2017. Petitioner stated the vaccine was administered in the United States, that she experienced residual effects of GBS for more than six months, and that there had been no prior award or settlement for her condition.
The respondent denied that petitioner's alleged GBS and residual effects were caused by the vaccine, suggesting that a concurrent upper respiratory illness was a more likely cause of GBS. Despite this dispute, the parties filed a joint stipulation on October 1, 2020, agreeing to an award of compensation.
Chief Special Master Brian H. Corcoran adopted the stipulation, awarding Lori Winn a lump sum of $55,000.00, payable to Petitioner, for all items of damages.
The decision was issued on November 2, 2020.
Theory of causation
Petitioner Lori Winn alleged Guillain-Barre Syndrome (GBS) following an influenza (flu) vaccination on November 2, 2017. Respondent denied causation, suggesting a concurrent upper respiratory illness was a more likely cause of GBS. The parties filed a joint stipulation agreeing to compensation. Chief Special Master Brian H. Corcoran adopted the stipulation, awarding a lump sum of $55,000.00 to Petitioner. The public decision does not describe the specific mechanism of GBS, any expert testimony, or detailed medical evidence supporting either party's theory. The decision date was November 2, 2020. Petitioner's counsel was Jeffrey S. Pop, and respondent's counsel was Voris Edward Johnson.
Source PDFs
USCOURTS-cofc-1_18-vv-01843